D-dimer levels in patients with and without APAs
| . | Median (IQR) . | P . | |
|---|---|---|---|
| APA− . | APA+ . | ||
| Enrollment; all patients on anticoagulants | |||
| Any APA vs no APA | 110 (110-275) | 110 (110-285) | .69 |
| ACA vs no ACA | 110 (110-270) | 110 (110-320) | .69 |
| Anti-β2GP1 vs no anti-β2GP1 | 110 (110-280) | 110 (110-110) | .20 |
| LA vs no LA | 110 (110-240) | 110 (110-260) | .32 |
| 1 month; negative qualitative D-dimer at enrollment and stopped anticoagulants | |||
| Any APA vs no APA | 310 (110-440) | 325 (240-430) | .37 |
| ACA vs no ACA | 310 (110-430) | 360 (240-900) | .13 |
| Anti-β2GP1 vs no anti-β2GP1 | 310 (110-430) | 440 (240-640) | .63 |
| LA vs no LA | 310 (110-440) | 310 (230-390) | .88 |
| 7 months; negative qualitative D-dimer at enrollment and stopped anticoagulants, and negative qualitative D-dimer at 1 month and remained off anticoagulants | |||
| Any APA vs no APA | 320 (110-540) | 340 (245-535) | .38 |
| ACA vs no ACA | 330 (110-540) | 340 (290-520) | .63 |
| Anti-β2GP1 vs no anti-β2GP1 | 330 (220-540) | 230 (110-350) | .42 |
| LA vs no LA | 330 (110-550) | 330 (230-450) | .82 |
| . | Median (IQR) . | P . | |
|---|---|---|---|
| APA− . | APA+ . | ||
| Enrollment; all patients on anticoagulants | |||
| Any APA vs no APA | 110 (110-275) | 110 (110-285) | .69 |
| ACA vs no ACA | 110 (110-270) | 110 (110-320) | .69 |
| Anti-β2GP1 vs no anti-β2GP1 | 110 (110-280) | 110 (110-110) | .20 |
| LA vs no LA | 110 (110-240) | 110 (110-260) | .32 |
| 1 month; negative qualitative D-dimer at enrollment and stopped anticoagulants | |||
| Any APA vs no APA | 310 (110-440) | 325 (240-430) | .37 |
| ACA vs no ACA | 310 (110-430) | 360 (240-900) | .13 |
| Anti-β2GP1 vs no anti-β2GP1 | 310 (110-430) | 440 (240-640) | .63 |
| LA vs no LA | 310 (110-440) | 310 (230-390) | .88 |
| 7 months; negative qualitative D-dimer at enrollment and stopped anticoagulants, and negative qualitative D-dimer at 1 month and remained off anticoagulants | |||
| Any APA vs no APA | 320 (110-540) | 340 (245-535) | .38 |
| ACA vs no ACA | 330 (110-540) | 340 (290-520) | .63 |
| Anti-β2GP1 vs no anti-β2GP1 | 330 (220-540) | 230 (110-350) | .42 |
| LA vs no LA | 330 (110-550) | 330 (230-450) | .82 |
IQR, interquartile range.